Treatment of Early Stage Hormone Receptor Positive Breast Cancer

  • Treatment strategies for early-stage hormone receptor positive / human epidermal receptor 2 negative (HR+/HER2-) breast cancer comprise definitive local therapy (primary surgical management of the breast and axilla with or without adjuvant radiation), and adjuvant endocrine therapy with or without chemotherapy
  • Nearly all patients with early-stage, HR+ breast cancers should be considered as candidates for adjuvant endocrine therapy
  • Conversely, adjuvant chemotherapy is considered only in a subgroup of patients with HR+/HER2- early breast cancer, based on the predicted risk for recurrence; the expected benefit from chemotherapy; and patient-specific factors, such as comorbidities.
  • In very select cases, neoadjuvant endocrine therapy or chemotherapy may be an option for patients with early-stage HR+ disease prior to surgery.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s